The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Janssen Pharmaceuticals, one of the pharmaceutical companies of Johnson & Johnson, has formed a license and collaboration deal with Arrowhead Pharmaceuticals, a Pasadena, California-based biotechnology company, to develop and commercialize...
GlaxoSmithKline (GSK) has signed a three-year clinical manufacturing agreement with Hitachi Chemical Advanced Therapeutics Solutions (HCATS), an Allendale, New Jersey-based contract development and manufacturing organization.
Under the agreement,...
Novo Nordisk is planning staff reductions of approximately 250 employees in the US as part of a reorganization resulting from an assessment of resource needs against its business priorities. Last month (September 2018), the company announced staff...
Merck & Co. and Dragonfly Therapeutics, a Waltham, Massachusetts-based company specializing in cancer immunotherapies, have partnered to discover, develop, and commercialize immunotherapies for patients with solid tumor cancers in a deal worth...
Sanofi has completed its previously announced divestment of its European generics business, Zentiva, to Advent International, a Boston-based private-equity firm, for approximately EUR 1.9 billion ($2.2 billion). The transaction was finalized ahead...
Roche has acquired Tusk Therapeutics, a Stevenage, UK-based pharmaceutical company focused on immuno-oncology, in a deal worth up to EUR 659 million ($759 million) ($80 million upfront and $675 million). Tusk has developed an antibody with a mode...
Merck & Co. and Accenture, a management consulting company, have partnered with Amazon Web Services (AWS) to launch a cloud-based informatics research platform designed to help organizations in the life-sciences industry improve productivity,...
The European Medicines Agency (EMA) has revised the number of centrally authorized medicines (CAPs) for which there are concerns of supply disruptions due to the UK’s exit from the European Union (EU) (i.e., Brexit) from 108 to 39. The revision...
Novo Nordisk plans to establish a manufacturing site in Fremont, California to develop and produce stem cell-based therapies. The company has signed a long-term lease on a GMP facility, previously operated by Asterias Biotherapeutics, a...
Ian Read, Chief Executive Officer and Chairman, Pfizer will step down as CEO, effective January 1, 2019, with Albert Bourla, the company’s current Chief Operating Officer (COO), assuming the role of CEO. Read will transition from his current role...
Dr. Reddy’s Laboratories, a Hyderabad, India-headquartered pharmaceutical company, has sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee to Neopharma, a pharmaceutical company headquartered in Abu Dhabi, United...
Following a court ruling, Fresenius, a specialty and generic pharmaceuticals company, has legally terminated its $4.75-billion merger with Akorn, a Lake Forest, Illinois-headquartered specialty generic pharmaceutical company. In April 2018,...
Novartis has announced staff reductions in manufacturing and business services operations in Switzerland and manufacturing in the UK.
The company explained the rationale for the changes and the staff reductions planned. “In a continuation...
Takeda plans to close its US headquarters in Deerfield, Illinois and move its functions to the Boston area. The move follows Takeda’s proposed $62-billion acquisition of Shire, announced in May 2018, which is scheduled to be completed in the first...
The European Commission (EC) has granted marketing authorization for Hulio (adalimumab), a biosimilar to AbbVie's Humira (adalimumab), an anti-inflammatory drug, for all indications, to Mylan and Fujifilm Kyowa Kirin Biologics Co., a biosimilars...
